In muscle and adipose tissue, GLP-1RA increases insulin sensitivity, promotes glucose uptake and utilization, and reduces the release of free fatty acids (FFA) produced by fat breakdown
However, they must be used under the guidance of qualified healthcare professionals, as individual responses vary and careful monitoring is essential
Some people notice subtle changes, such as improved sleep, energy, or appetite control, within days to a few weeks
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
